Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses results from the Phase Ib/II trial (NCT03601897) investigating rebastinib and paclitaxel for advanced or metastatic ovarian cancer. Oral rebastinib was combined with standard-of-care paclitaxel chemotherapy, with patients receiving either 50mg BID or 100mg BID of rebastinib. Promising progression-free survival was seen and the most common side effects were due to chemotherapy, which was manageable at a dose of 50mg BID. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.